RealFeedApp beta
- Shortening cell expansion cuts CAR T-therapy production to 10 days
Reducing the 10–21 day expansion phase in CAR T-cell therapy production lowers the dose required and speeds up delivery, addressing the fact that 30% of annual therapies go unused due to patient deterioration.
- Field
- gene therapy
- What they did
- Researchers demonstrated that shortening the cell expansion phase in CAR T-cell therapy production can deliver more effective, lower-dose treatments faster to patients.
- Why it matters
- This is crucial because 30% of annual therapies go unused as patients' health declines during the current 10–21 day production wait.
#car t-cell#gene therapy#cell expansion#fda approval
